Computational chemistry news from Cresset, featuring Blaze V10.3 released for even better virtual screening
Cresset publishes September 2017 newsletter
Blaze V10.3 released for even better virtual screening
The latest version of Blaze™, our virtual screening platform is now available. V10.3 introduces pharmacophore constraints to enable you to find the best possible new hits and leads. Alongside pharmacophore constraints, we’ve added additional similarity metrics and updated the user interface.
Sneak peek at Forge V10.5
New versions (V10.5) of Forge™ and Torch™ are due out next month. This release offers new science and functionality and plenty of improvements that significantly enhance both applications. Here we offer a sneak peek at some of the new functionality in Forge.
Flare enhances the Cresset Discovery Services toolbox
What does Flare™, our new structure-based design application, offer Cresset Discovery Services that it didn’t have before?
- 3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7, Nature Scientific Reports
- Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1, Bioorganic & Medicinal Chemistry Letters
- Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1, Journal of Medicinal Chemistry
- Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family, Bioorganic & Medicinal Chemistry Letters
Back to school offer
Up to 25% off academic research licenses on all orders received by October 31, 2017.
Commercial Director to run 32nd half marathon
On October 1, 2017, David Bardsley, our Commercial Director will run his 32nd half marathon in Cardiff, UK. We’re delighted to sponsor David in raising funds for cancer research at Cardiff University.
Computational solutions for drug discovery